# ![@FormalyTwilter Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1885336611560579072.png) @FormalyTwilter 佐藤雄二

佐藤雄二 posts on X about $aspi, $tlph, $qure, $vnda the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1885336611560579072/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1885336611560579072/c:line/m:interactions.svg)

- [--] Week [------] +224%
- [--] Month [------] +570%
- [--] Months [-------] -2.60%
- [--] Year [---------] +54,170%

### Mentions: [--] [#](/creator/twitter::1885336611560579072/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1885336611560579072/c:line/m:posts_active.svg)

- [--] Week [--] +277%
- [--] Month [---] +400%
- [--] Months [---] +47%
- [--] Year [---] +9,400%

### Followers: [---] [#](/creator/twitter::1885336611560579072/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1885336611560579072/c:line/m:followers.svg)

- [--] Week [---] +0.85%
- [--] Month [---] +3.70%
- [--] Months [---] +0.43%

### CreatorRank: [---------] [#](/creator/twitter::1885336611560579072/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1885336611560579072/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  53.27% [finance](/list/finance)  19.63% [countries](/list/countries)  5.61% [cryptocurrencies](/list/cryptocurrencies)  5.61% [technology brands](/list/technology-brands)  4.67% [financial services](/list/financial-services)  3.74% [social networks](/list/social-networks)  0.93%

**Social topic influence**
[$aspi](/topic/$aspi) 9.35%, [$tlph](/topic/$tlph) 8.41%, [$qure](/topic/$qure) #23, [$vnda](/topic/$vnda) #10, [$nktr](/topic/$nktr) #64, [$eton](/topic/$eton) 6.54%, [eton](/topic/eton) 6.54%, [$xbi](/topic/$xbi) 5.61%, [data](/topic/data) 4.67%, [stocks](/topic/stocks) 4.67%

**Top accounts mentioned or mentioned by**
[@9investobey](/creator/undefined) [@mmatters22596](/creator/undefined) [@biostocks](/creator/undefined) [@grok](/creator/undefined) [@stocknear](/creator/undefined) [@aleabitoreddit](/creator/undefined) [@biotechautist](/creator/undefined) [@asamimes](/creator/undefined) [@brianskorney](/creator/undefined) [@leerinkpartners](/creator/undefined) [@clearstreetnews](/creator/undefined) [@takayamajoe](/creator/undefined) [@cluelessbio](/creator/undefined) [@denebulord](/creator/undefined) [@zethedeuce](/creator/undefined)

**Top assets mentioned**
[ASP Isotopes Inc. (ASPI)](/topic/$aspi) [uniQure N.V. (QURE)](/topic/$qure) [Tyra Biosciences, Inc. (TYRA)](/topic/$tyra) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Skyline Builders Group Holding Limited (SKBL)](/topic/$skbl) [Eli Lilly and Company (LLY)](/topic/$lly) [Goldman Sachs (GS)](/topic/goldman-sachs) [Duolingo, Inc.  (DUOL)](/topic/$duol) [Apogee Therapeutics, Inc. (APGE)](/topic/$apge) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Nuvation Bio Inc. (NUVB)](/topic/$nuvb) [GRAIL, Inc. Common Stock (GRAL)](/topic/$gral) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Biofrontera Inc. (BFRI)](/topic/$bfri) [Huma Finance (HUMA)](/topic/$huma) [Aardvark Therapeutics, Inc (AARD)](/topic/$aard) [Evommune, Inc. (EVMN)](/topic/$evmn) [Vertex Protocol (VRTX)](/topic/$vrtx) [Origin Protocol (OGN)](/topic/$ogn) [Fractyl Health, Inc. (GUTS)](/topic/$guts) [Alto Neuroscience, Inc. (ANRO)](/topic/$anro) [Amgen, Inc. (AMGN)](/topic/$amgn) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) [United Airlines Holdings, Inc. (UAL)](/topic/$ual) [Tyler Technologies, Inc. (TYL)](/topic/$tyl) [GammaSwap (GS)](/topic/$gs) [Reddit, Inc.  (RDDT)](/topic/$rddt) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Kyverna Therapeutics, Inc. (KYTX)](/topic/$kytx) [Turn Therapeutics, Inc. (TTRX)](/topic/$ttrx) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$CLPT $CLPT BBB ( )  ( ) ( ) @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably more risk. @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably"  
[X Link](https://x.com/FormalyTwilter/status/2020593582000984237)  2026-02-08T20:20Z [---] followers, [---] engagements


"$CLPT ( ) 3%5-7%  @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably more risk. @9_Invest_obey $CLPT is and will be the default platform to deliver meds past the BBB. Any drug needing to be delivered to the brain will be utilizing their technology. Big upside. That said it is 3% of my portfolio and may increase to 5-7%. All in anything includes unmeasurably more risk"  
[X Link](https://x.com/FormalyTwilter/status/2020593878588670151)  2026-02-08T20:21Z [---] followers, [---] engagements


"#Iran #Uranium #HEU 400HEU Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s Iran official says Tehran considering handing over [---] kg of highly enriched uranium (HEU) accepting zero enrichment under a consortium arrangement as a solution in a deal that should also include lifting economic sanctions https://t.co/ESN8OQiS9s"  
[X Link](https://x.com/FormalyTwilter/status/2022420021931315579)  2026-02-13T21:18Z [---] followers, [---] engagements


"# # # Consolidated financial results for the fiscal year ending December Otsuka Holdings' net profit increases [---] times. Net profit and sales both reach record highs with pharmaceuticals performing well. #OtsukaPharmaceutical #Otsuka $ESPR # # # HD28 [--] https://t.co/1piRenXK3r # # # HD28 [--] https://t.co/1piRenXK3r"  
[X Link](https://x.com/FormalyTwilter/status/1962212387702087780)  2025-08-31T17:54Z [---] followers, [---] engagements


"$ANRO #ALTO-101 ALTO-101   PDE4 PDE4 cAMP   ( )"  
[X Link](https://x.com/FormalyTwilter/status/2013351829799870742)  2026-01-19T20:44Z [---] followers, [---] engagements


"$ASPI $QLE $SKBL ( ) TerraPower $ASPI  $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand."  
[X Link](https://x.com/FormalyTwilter/status/2017234894271951268)  2026-01-30T13:54Z [---] followers, [---] engagements


"$SKBL $SKBL [--] Panamax 220DOE DOE LPO60-70% IP $ASPI #SKBL #Uranium Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI Mandatory listen for all $SKBL investors: 2.2m lbs of uranium per year from [--] Panamax deployment. DOE tech. Supporting US domestic uranium supply. Highly confident about DOE LPO loan. Would cover 60-70% capex. Developing IP for suite of other metals. $ASPI"  
[X Link](https://x.com/FormalyTwilter/status/2018272383216627984)  2026-02-02T10:36Z [---] followers, [----] engagements


"$AGIO 400060% [----] [--]  @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here. @stocknear There are [----] patients of thalassemia in USA . [--] percent are transfusion dependent. So at this price revenue should easily cross a billion dollars in USA alone in about [--] months.The market cap is [---] billion. Stock should easily double from here"  
[X Link](https://x.com/FormalyTwilter/status/2019086609501610224)  2026-02-04T16:32Z [---] followers, [---] engagements


"$AGIO AgiosPharmaceuticals FDA   AQVESME  AQVESME [-------] $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year. $AGIO Agios Pharmaceuticals shares are trading higher after the company announced the FDA approved AQVESME for the treatment of anemia in adults with alpha- or beta-thalassemia. An exect announced AQVESME will be introduce at approximately $425000 per patient per year"  
[X Link](https://x.com/FormalyTwilter/status/2019087618299105594)  2026-02-04T16:36Z [---] followers, [---] engagements


"$NKTR $QURE ( ) Catalist   Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before my https://t.co/1tBX30s0Ae Actually I decided to start the fun early. Bot some $NKTR calls for maintenance data play and $QURE calls for FDA Type A meeting minutes play. Both fairly uncorrelated with broader market and charts look decent for bottom fishing with appropriate catalysts in place before"  
[X Link](https://x.com/FormalyTwilter/status/2019149142585704883)  2026-02-04T20:40Z [---] followers, [----] engagements


"$LLY  ( EliLilly )2026 Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR Even with pricing headwinds Eli Lilly expects sales surge to continue in [----] https://t.co/AYFOXbf9NR"  
[X Link](https://x.com/FormalyTwilter/status/2019151935157465449)  2026-02-04T20:51Z [---] followers, [--] engagements


"#FDA $AMGN #Amgen FDA Phase3 Amgen Tavneos - - FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z FDA rehashing old Ph3 data and seeking to withdrawal of Amgen's Tavneos but company says it won't pull drug - very weird very unprecedented - https://t.co/trwypcvk6Z"  
[X Link](https://x.com/FormalyTwilter/status/2019163874931667326)  2026-02-04T21:39Z [---] followers, [---] engagements


"$TYRA #OPPENHEIMER MatthewBiegler $TYRA AnaChart [------] 3#Pricetarget $36$50  $4.98 (16.05%) $18.98 (61.19%)  Outperform #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an increase in potential upside change from $4.98(16.05%) to $18.98(61.19%) with a rating of Outperform https://t.co/W9u958dQnd #OPPENHEIMER analyst Matthew Biegler who covers $TYRA has the current 3rd biggest #pricetarget movement on AnaChart (03-Feb-2026 (10AM)) by upgrading from $36 to $50 with an"  
[X Link](https://x.com/FormalyTwilter/status/2019327751719911736)  2026-02-05T08:30Z [---] followers, [--] engagements


"$TYRA - Phase2 🚀 ➤ -0.88% +11.33% - ➤ RVOL [----] - ➤ [-----] / 17.65% -  $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU $TYRA dosed first child in Phase 2; shares surge 🚀 ➤ +11.33% intraday after a -0.88% gap momentum confirmed ➤ RVOL [----] above-average trading interest ➤ Short Ratio [-----] / Short Float 17.65% meaningful short-squeeze risk https://t.co/RfRZyPogmU"  
[X Link](https://x.com/FormalyTwilter/status/2019328462776049866)  2026-02-05T08:33Z [---] followers, [--] engagements


"$TYRA BiotechAnalyst ChrisRaymond $TYRA Layering UTUC Into Our Dabogratinib Model$TYRA Dabogratinib  Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first approved indication for dabogratinib. Biotech analyst Chris Raymond published on $TYRA "Layering UTUC Into Our Dabogratinib Model" calling out that although this is smaller opportunity TYRA can accelerate development here with the potential for this to be the first"  
[X Link](https://x.com/FormalyTwilter/status/2019331900352131334)  2026-02-05T08:46Z [---] followers, [--] engagements


"$ASPI  PDRadiopharma PSMA *1  mCRPC  177Lu-PSMA-I&T  Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic castration-resistant prostate cancer (mCRPC) $ASPI https://t.co/Anw7EPIg7l Curium today announced that together with PeptiDream and PDRadiopharma the first patient has been dosed in the companies registrational clinical trial of 177Lu-PSMA-I&T in Japan for patients with PSMA (*1)-positive metastatic"  
[X Link](https://x.com/FormalyTwilter/status/2019347140406112543)  2026-02-05T09:47Z [---] followers, [----] engagements


"$ALXO Director [---] Catalist ( )  Phase2 [--] - + - ( ASPEN-09-Breast ) HER2 Phase1  [----] - ALX2004 - $XBI $IBB $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB https://t.co/m1ID3Ym3kJ $ALXO Director acquires $5 million dollars at open market Catalyst: Phase [--] interim data Q3 -Evorpacept + trastuzumab - (ASPEN-09-Breast) HER2-positive metastatic breast cancer Phase [--] 1H [----] ALX2004 Solid Tumors $XBI $IBB"  
[X Link](https://x.com/FormalyTwilter/status/2019349321813283029)  2026-02-05T09:56Z [---] followers, [---] engagements


"$SRPT $SRPT  SRP-1005 $QURE $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw $SRPT Announces Approval of Clinical Trial Application for SRP-1005 Its Investigational Treatment for Huntingtons Disease. $QURE https://t.co/vhXhb1HcMw"  
[X Link](https://x.com/FormalyTwilter/status/2019349998761308273)  2026-02-05T09:58Z [---] followers, [----] engagements


"$QURE 10:30   $QURE [----] tomorrow. Thats when we get data $QURE [----] tomorrow. Thats when we get data"  
[X Link](https://x.com/FormalyTwilter/status/2019869412082479278)  2026-02-06T20:22Z [---] followers, [---] engagements


"$QURE AMT-191 $QURE  ( ) AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be"  
[X Link](https://x.com/FormalyTwilter/status/2019874484954787926)  2026-02-06T20:42Z [---] followers, [---] engagements


"$QURE ( ) HD FDA  AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key. https://t.co/4A3R2vip6X AMT-191 active drug dose-limiting toxicity (liver enzymes) but seems manageable. $QURE have to collect more data to substantiate the long-term medical benefits with an acceptable safety profile. Early solid data but no home run. Short term the FDA feedback on HD will be key."  
[X Link](https://x.com/FormalyTwilter/status/2019874644166340701)  2026-02-06T20:43Z [---] followers, [---] engagements


"$WVE CantorFitzgerald Webinar $WVE WV-007 [-----] - - BMI100 $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients. $WVE: Listening to the Cantor Fitzgerald webinar with $WVE management. WV-007 data coming up is very impressive and they're excited. Confirmed it will be in Q1 [----]. -Great differentiated data. -Accelerating higher BMI fully enrolled study w/ [---] patients"  
[X Link](https://x.com/FormalyTwilter/status/2020030929071411265)  2026-02-07T07:04Z [---] followers, [---] engagements


"$EIKN 200IPO $MRK 10% $XBI $IBB $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap $EIKN Director acquires $2 million bucks at open market Fresh ipo. $MRK also took at 10% stake $XBI $IBB https://t.co/QlTNpPu5Ap"  
[X Link](https://x.com/FormalyTwilter/status/2020035123950006533)  2026-02-07T07:21Z [---] followers, [---] engagements


"$TYRA - Jefferies TyraBiosciences  ( PT ) $32$43  :  $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from $153 Buy - $TYL -Needham reiterates Tyler Technologies $750 target Buy -DA Davidson maintains $510 target Neutral - $TYRA -Jefferies raises Tyra Biosciences target to $43 from $32 Buy - $UAL -Citi adds United Airlines to upside [--] day catalyst watch Raises target to $155 from"  
[X Link](https://x.com/FormalyTwilter/status/2020524300034343239)  2026-02-08T15:45Z [---] followers, [--] engagements


"#SPX #Stocks  S&P500 CTA   STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week"  
[X Link](https://x.com/FormalyTwilter/status/2020597530829148649)  2026-02-08T20:36Z [---] followers, [---] engagements


"#SPX #Stocks $GS CTA [---] - S&P500 [---]  STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week STOCK SELL-OFF NOT OVER GOLDMAN TRADERS SAY Goldman Sachs warns that US stocks could face more selling this week driven by trend-following funds known as CTAs which have already hit sell triggers in the S&P [---]. The bank estimates CTAs could dump up to $33 billion this week"  
[X Link](https://x.com/FormalyTwilter/status/2020598291533312296)  2026-02-08T20:39Z [---] followers, [---] engagements


"$BFRI [---] Q4 [----]  $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races $BFRI looking juicy here. Trading just below 1x sales with multiple approvals next [--] months and breakeven this year. Beat q4 estimates and I suspect they hit closer to 50mm this year then its off to the races"  
[X Link](https://x.com/FormalyTwilter/status/2020835306057126087)  2026-02-09T12:20Z [---] followers, [---] engagements


"@aleabitoreddit $RDDT"  
[X Link](https://x.com/FormalyTwilter/status/2020839611652853949)  2026-02-09T12:38Z [---] followers, [---] engagements


"$AXSM [--] $AXSM ADA [---] PDUFA  More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk More unusual $AXSM options activity for February and March. Someone betting that a potential buyout happens before the April 30th PDUFA for ADA https://t.co/Lk3eAThcnk"  
[X Link](https://x.com/FormalyTwilter/status/2020843104878862840)  2026-02-09T12:51Z [---] followers, [---] engagements


"$ETON 2026-02-09 : $14.76 PDUFA : 2026-02-25 ET-600 ( ( ) ) PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600    PoA: 85% 2026-02-25 $ETON 14.76$ PDUFA Date ET-600    PoA: 85%"  
[X Link](https://x.com/FormalyTwilter/status/2020867244696215998)  2026-02-09T14:27Z [---] followers, [--] engagements


"$ETON  Catalist - 2026-02-25  - ET-600  -  PoA85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85% https://biopharmawatch.com/company/ETON $ETON https://t.co/lwNT8GmOXU Catalyst Date - 2026-02-25 Drug - ET-600 (desmopressin oral solution) Treatment - central diabetes insipidus Poa : 85%"  
[X Link](https://x.com/FormalyTwilter/status/2020867860298436619)  2026-02-09T14:30Z [---] followers, [---] engagements


"$ETON    [---] ( 200DMA )  Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8 Eton pharma $eton new rare disease drug upcoming. Chart not far from breakout. We are below 200D so quarterly results better be good. https://t.co/zYWKjIkOE8"  
[X Link](https://x.com/FormalyTwilter/status/2020868956655878214)  2026-02-09T14:34Z [---] followers, [--] engagements


"$ETON +3.75% EtonPharmaceuticals [---]  FDA [----]  https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and mid-2026 launch as first generic alternative. https://t.co/TRnDNA9ZxD https://t.co/h6ZQbBJrLH https://notreload.xyz/eton-pharma-licenses-first-generic-ultra-rare-disease-drug/ $ETON +3.75% Eton Pharmaceuticals licenses U.S. rights to an ultra-rare disease treatment affecting under [---] patients expecting FDA approval and"  
[X Link](https://x.com/FormalyTwilter/status/2020869546299547704)  2026-02-09T14:37Z [---] followers, [--] engagements


"$ETON   $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn $ETON Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate https://t.co/9B4jYttsJn"  
[X Link](https://x.com/FormalyTwilter/status/2020870201902760196)  2026-02-09T14:39Z [---] followers, [--] engagements


"$ETON $KYTX $ETON 2/25 PDUFA $KYTX  Phase2 BLA2026 Phase2  Catalist  @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026) @BiotechAutist @asamimes @BrianSkorney @LeerinkPartners @ClearStreetNews Well $ETON has PDUFA on2/25. $KYTX has a nr of potential catalysts with readings (Ph2 stiff person syndrome BLA filling interim Ph2 myasthenia gravis extended in 2026)"  
[X Link](https://x.com/FormalyTwilter/status/2020870937193665009)  2026-02-09T14:42Z [---] followers, [---] engagements


"$BFRI - Phase3 Ameluz 85%12% sNDA [-----] Catalist  $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst. $BFRI - Phase [--] Ameluz results are in 85% complete response rate but stock's down 12% today. sNDA submission planned for Q3 [----] that's the next catalyst"  
[X Link](https://x.com/FormalyTwilter/status/2020871919017644170)  2026-02-09T14:46Z [---] followers, [---] engagements


"$TTRX - GX-03 Phase2 FDA Medline/MiMedx [----] 6.5%   Phase3 [----] $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for [----]. $TTRX - GX-03 Phase [--] hits FDA clears path 70M+ partnership with Medline/MiMedx is a nice boost. Still stock's down 6.5% today maybe due to high expectations. Phase [--] for eczema and onychomycosis is next slated for 2027"  
[X Link](https://x.com/FormalyTwilter/status/2020872464864079954)  2026-02-09T14:48Z [---] followers, [--] engagements


"$HUMA Humacyte DOD [----] $Huma #Israel #Iran #Ukraine http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in Isreal should be approved in next 60-90 days or faster. $Huma #Israel #Iran #Ukraine https://t.co/1psvbFahOa https://t.co/hwzljqLJLe http://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-new-us-department-defense-funding-procurement/ Humacyte announced DOD funding. Plus they have filed to be able to sell in"  
[X Link](https://x.com/FormalyTwilter/status/2020878119553683465)  2026-02-09T15:11Z [---] followers, [---] engagements


"$HUMA $HUMA DOD   12%   $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS $HUMA surges 12% on DOD funding for its bioengineered vessels but the numbers demand caution: This is a speculative move on a procurement bill not revenue. Wait for real confirmation before trading the volatility. https://t.co/3j6bWJ9vyS"  
[X Link](https://x.com/FormalyTwilter/status/2020878710250053840)  2026-02-09T15:13Z [---] followers, [---] engagements


"$DUOL $HIMS  80%  $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't https://t.co/PIiwzxkYA7 $DUOL seems to be the most hated stock in the entire market right now (excluding $HIMS). Yet the only argument I here is that it's down 80% from highs which for most investors means it must be trash. But take a look at the balance sheet. This company is dirt-cheap and won't"  
[X Link](https://x.com/FormalyTwilter/status/2020940110519468446)  2026-02-09T19:17Z [---] followers, [---] engagements


"$DUOL $DUOL  @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6 @MMatters22596 Cool infographics what's interesting in $DUOL's case is especially its growth in terms of paid subscribers: it's booming https://t.co/MiqW0f8Zd6"  
[X Link](https://x.com/FormalyTwilter/status/2020940729187696791)  2026-02-09T19:19Z [---] followers, [---] engagements


"$DUOL  @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough @MMatters22596 The valuation is totally comical at this point. Anyone who still thinks this company is expensive has a poor feel for whats going on in the rest of the market and hasnt studied its financials enough"  
[X Link](https://x.com/FormalyTwilter/status/2020941021849452890)  2026-02-09T19:21Z [---] followers, [---] engagements


"$SOFI GBULBorrow EVP SoFiTechnologies  General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj General Counsel joins the EVP of GBUL Borrow in buying the dip at SoFi Technologies $SOFI https://t.co/DV7TCjG9Fj"  
[X Link](https://x.com/FormalyTwilter/status/2020944896572653820)  2026-02-09T19:36Z [---] followers, [---] engagements


"$LTRX $QCOM $TER $LTRX $QCOM $TER    $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB $LTRX so much Reason with $QCOM and $TER Thermal for Drones and Robotcis https://t.co/AuZRaDuQNB"  
[X Link](https://x.com/FormalyTwilter/status/2020945671839510675)  2026-02-09T19:39Z [---] followers, [--] engagements


"$CRVS $CRVS Ph1b/2 SQL 400mg QD [----] $CRVS Phase2 US/Global 400mg QD $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies. $CRVS CRVS's China partner is actively testing SQL 400mg QD in a Ph1b/2 study in China w/ topline data to come likely 2H26 which could provide early support for CRVS's planned 400mg QD cohort in Ph2 US/ global studies"  
[X Link](https://x.com/FormalyTwilter/status/2020952056866144278)  2026-02-09T20:04Z [---] followers, [---] engagements


"$VNDA - [---] PDUFA  $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG $vnda feb [--] PDUFA- likelyhood of advancing is high https://t.co/u116MGvCzG"  
[X Link](https://x.com/FormalyTwilter/status/2020968294833102913)  2026-02-09T21:09Z [---] followers, [---] engagements


"$VNDA [--] [--] $XBI $LLY $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy $VNDA should be trading 4x higher. 20x when the world discovers they have the numero uno late stage drug in the world that keeps obese people on their weight loss treatments.so sad this company has shitty management with little business acumen or marketing skills🤷♂ $XBI $LLy"  
[X Link](https://x.com/FormalyTwilter/status/2020969008368058771)  2026-02-09T21:12Z [---] followers, [---] engagements


"$ETON $VNDA [--] PDUFA $ETON $VNDA $XBI  Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries. Rough few days my focus will be on $ETON and $VNDA going into PDUFAs in Feb. $XBI Looking for good entries"  
[X Link](https://x.com/FormalyTwilter/status/2020969688520704198)  2026-02-09T21:14Z [---] followers, [---] engagements


"$CRVS $APGE $NKTR $KYMR  ( ) $NKTR + $KYMR /JAKi Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or required nave patients https://t.co/3IF66KMKGJ Key Differences Inclusion/Exclusion Criteria in Atopic Dermatitis Trials $CRVS Very high-bar patients w/ prior biologic/JAKi require failed therapy refractory $APGE Allows JAKi excludes prior IL-4/IL-13 $NKTR + $KYMR exlude prior biologics/JAKi or"  
[X Link](https://x.com/FormalyTwilter/status/2021138917504974895)  2026-02-10T08:27Z [---] followers, [---] engagements


"$AARD - Phase3 HERO [--] ToplineData [--] $BIOA $IBIO  $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting. $AARD - Expands Phase [--] HERO trial to kids 7+. Toline data still on track for Q3 competitive landscape with $BIOA and $IBIO getting interesting"  
[X Link](https://x.com/FormalyTwilter/status/2021220085587734642)  2026-02-10T13:49Z [---] followers, [---] engagements


"$AARD  ARD-101  Phase3 FDA IRB  $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m $AARD Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome https://t.co/ornKXpfW0m"  
[X Link](https://x.com/FormalyTwilter/status/2021220935684997280)  2026-02-10T13:53Z [---] followers, [--] engagements


"$EVMN - Evommune  EVO301 Phase2a  $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis. $EVMN - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis"  
[X Link](https://x.com/FormalyTwilter/status/2021221749845529082)  2026-02-10T13:56Z [---] followers, [--] engagements


"$VNDA VandaPharmaceuticals  HETLIOZ FDA  https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob https://pryzm.ozmosi.com/product/2117 $VNDA Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder More Info: https://t.co/zM6GMxghuK https://t.co/9CDllQv1ob"  
[X Link](https://x.com/FormalyTwilter/status/2021580953584345434)  2026-02-11T13:43Z [---] followers, [---] engagements


"$VRTX $VNDA Vertex [----] Jounravx [---] $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises $VRTX $VNDA Vertex plans to triple Jounravx patients to [---] million in [----] while expanding into pain and renal disease franchises"  
[X Link](https://x.com/FormalyTwilter/status/2021583261336502279)  2026-02-11T13:53Z [---] followers, [---] engagements


"$VRTX JOURNAVXsuzetrigine [--] NaV1.8"  
[X Link](https://x.com/FormalyTwilter/status/2021583656356061244)  2026-02-11T13:54Z [---] followers, [--] engagements


"$ASPI [---] Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ Goldman Sachs buys [-------] shares more of $ASPI https://t.co/sbrepJtISQ"  
[X Link](https://x.com/FormalyTwilter/status/2021584400060735824)  2026-02-11T13:57Z [---] followers, [---] engagements


"$ASPI BNPParibasAssetManagementUK files 13G disclosing ownership of close to 1mm shares of $ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI"  
[X Link](https://x.com/FormalyTwilter/status/2021585124748398861)  2026-02-11T14:00Z [---] followers, [---] engagements


"$ASPI BNPUK 13G$ASPI [---] $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI $ASPI BNP Paribas Asset Management UK files 13G disclosing ownership of close to 1mm shares of ASPI"  
[X Link](https://x.com/FormalyTwilter/status/2021585376104649039)  2026-02-11T14:01Z [---] followers, [---] engagements


"$MDGL [--] siRNA MASH [------] http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could reach US $4.4 billion https://t.co/hYvsykdfgp http://SuzhouRiboLifeScienceCo.Ltd $MDGL Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs with Suzhou Ribo Life Science Co. Lt US $60 million Upfront and cumulative payments across the programs could"  
[X Link](https://x.com/FormalyTwilter/status/2021586061198037215)  2026-02-11T14:04Z [---] followers, [---] engagements


"$ASPI  $ASPI   TaronisFuels IR $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo $ASPI I find it interesting that Michael Khorassani is also promoting ASPI for those who dont know he was doing IR for Taronis Fuels a proven industrial tech fraud. https://t.co/bhFufG56od https://t.co/nrF42YH4Jo"  
[X Link](https://x.com/FormalyTwilter/status/2021622313326882816)  2026-02-11T16:28Z [---] followers, [---] engagements


"$GELS Gelteq HealthyExtracts $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm $GELS Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership https://t.co/a6wM5mOovm"  
[X Link](https://x.com/FormalyTwilter/status/2021695973102067824)  2026-02-11T21:20Z [---] followers, [--] engagements


"$VNDA 📉 ⚡ 7/10 : $VNDA4 💡 VNDA10.1% 👉 #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA declining [----] 👉 https://t.co/M6U3eWkjtJ #Traders #Hours #Stocks https://fibalgo.com/terminal 📉 BEARISH ⚡ 7/10 After-hours healthcare small-caps volatile; VNDA drops on Q4 earnings $VNDA 💡 The news highlights significant after-hours price movements in low-market-cap healthcare stocks with VNDA"  
[X Link](https://x.com/FormalyTwilter/status/2021704202121330950)  2026-02-11T21:53Z [---] followers, [---] engagements


"$VNDA Vanda VQW-765 YE26 Phase3 Phobia Social  $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf $VNDA Vanda announced they will present P3 Phobia Social results in YE26 for VQW-765 More Info: https://t.co/YkHjDciIlR https://t.co/Y3A6l8KLcf"  
[X Link](https://x.com/FormalyTwilter/status/2022045512900419966)  2026-02-12T20:29Z [---] followers, [--] engagements


"$NKTR Rezpegaldesleukin Rezpeg NektarTherapeutics T RegulatoryTcell : Treg IL-2 ( )"  
[X Link](https://x.com/FormalyTwilter/status/2022064724628893979)  2026-02-12T21:46Z [---] followers, [---] engagements


"$NKTR ( )  IL-13    Rezpeg First-in-class Treg"  
[X Link](https://x.com/FormalyTwilter/status/2022064999393534282)  2026-02-12T21:47Z [---] followers, [---] engagements


"$OGN Organon 2025Q4 📊 ❌ EPS: $0.63 : 30.00% (from $0.90) ❌ : $1.507B : 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B) 📊 Organon $OGN Q4 [----] Earnings ❌ Earnings Miss Adj. EPS: $0.63 YoY: 30.00% (from $0.90) ❌ Revenue Miss Sales: $1.507B YoY: 5.34% (from $1.592B)"  
[X Link](https://x.com/FormalyTwilter/status/2022166180346372106)  2026-02-13T04:29Z [---] followers, [--] engagements


"$OGN [------]   Nexplanon 7% $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today. $OGN - [----] revenue hits $6.2B Launched new biosimilars and chopped debt. Nexplanon patents expire soon though and that's a big chunk of revenue. Down 7% today"  
[X Link](https://x.com/FormalyTwilter/status/2022167271632990264)  2026-02-13T04:33Z [---] followers, [--] engagements


"$ASPI  $ASPI [---] BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN BlackRock buys [----] millions shares more of $ASPI https://t.co/5Tkywq81yN"  
[X Link](https://x.com/FormalyTwilter/status/2022301289670180878)  2026-02-13T13:26Z [---] followers, [----] engagements


"$OCUL $OCUL AXPAXLI AMD  SOL-1 Phase3   [-----] [--]  $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th $OCUL topline results of the SOL-1 Phase [--] superiority clinical trial of AXPAXLI for the treatment of wet AMD are expected to be presented at the 49th Macula Society Annual Meeting taking place between Feb 25th 28th"  
[X Link](https://x.com/FormalyTwilter/status/2022316832246710440)  2026-02-13T14:28Z [---] followers, [---] engagements


"$OCUL ( ) - [--] SOL-R Phase3 [---] 1Q'27 $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase [--] $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase 3"  
[X Link](https://x.com/FormalyTwilter/status/2022317795741167923)  2026-02-13T14:31Z [---] followers, [---] engagements


"$NUVB NuvationBio IDH1 Safusidenib  Phase3 SIGMA G203   https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM https://pryzm.ozmosi.com/product/22745 $NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://t.co/ybrR3GaTOQ https://t.co/4ABtiXo1GM"  
[X Link](https://x.com/FormalyTwilter/status/2020938306322829398)  2026-02-09T19:10Z [---] followers, [---] engagements


"$NUVB IDH1  ( Safusidenib ) Phase3  G203  $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix $NUVB Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma https://t.co/Xk3LO2x2ix"  
[X Link](https://x.com/FormalyTwilter/status/2020943783182074328)  2026-02-09T19:31Z [---] followers, [---] engagements


"$VNDA Vanda Milsaperidone   Phase3 YE26  $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW $VNDA Vanda announced they will present P3 Depressive Disorder Major results in YE26 for Milsaperidone More Info: https://t.co/5cBb1LRf5w https://t.co/nH2ssEtTAW"  
[X Link](https://x.com/FormalyTwilter/status/2022046139214950417)  2026-02-12T20:32Z [---] followers, [---] engagements


"$OCUL SOL-1Phase3  - SOL-1 [--]  - SOL-1 [--] WetAMD AXPAXLI NDA ( ) $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of [---] subjects in SOL-R Phase [--] $OCUL SOL-1 Phase [--] superiority trial results remain masked to date - SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting - Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 [--] Week data - Completed randomization of 631"  
[X Link](https://x.com/FormalyTwilter/status/2022317458577916262)  2026-02-13T14:30Z [---] followers, [---] engagements


"$KYMR $CRVS $APGE Phase2b AD   ( ) Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance"  
[X Link](https://x.com/FormalyTwilter/status/2022422074376216772)  2026-02-13T21:26Z [---] followers, [---] engagements


"$KYMR $CRVS $APGE $NKTR ( ) - $KYMR KT-6211652 $CRVS #1230 - $APGE $NKTR [----] Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE $NKTR 16wk data [--] wk maintenance https://t.co/EocGY0UPie Different Ph2b AD trial designs orals may take less time than injectables and close gap w/ injectable programs further ahead oral $KYMR KT-621 [--] wks [--] wk open label extension $CRVS #soquelitinib [--] wks 30-day follow-up inj $APGE"  
[X Link](https://x.com/FormalyTwilter/status/2022422377184006630)  2026-02-13T21:27Z [---] followers, [---] engagements


"$QURE - FDA  150% vs  30% $QURE AMT-130 AA $CLPT $CLPT [--] $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for"  
[X Link](https://x.com/FormalyTwilter/status/2019090936052228237)  2026-02-04T16:49Z [---] followers, [---] engagements


"$QURE     $QURE $CLPT  $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the $QURE potential stock moving catalyst- FDA meeting updates Potential upside 150% vs downside 30% Another stock that would surge big is $CLPT if $QURE gets the AA for AMT-130 $CLPT could more than double on positive news because it will be the confirmatory evidence for the"  
[X Link](https://x.com/FormalyTwilter/status/2019091211034988608)  2026-02-04T16:50Z [---] followers, [----] engagements


"$XBI / $ARDX $DAWN $SLNO $TMDX $HROW   #ARDX #DAWN #SLNO #TMDX #HROW #XBI $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW $XBI few small cap biotech companies that still seems undervalued with approved drug (s) on the market. De-risked as earnings and drug launches have done better than before $ARDX $DAWN $SLNO $TMDX $HROW"  
[X Link](https://x.com/FormalyTwilter/status/2020894097624678608)  2026-02-09T16:14Z [---] followers, [--] engagements


"$CRVS  ITK #Soquelitinib AD 🔹 🔹 EASI-75 🔹 $NKTR $KYMR $EVMN  $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing signals that you can get durative efficacy" https://t.co/6WkozViVTB $CRVS Mizuho discusses oral ITK inhibitor #soquelitinib recent AD data: 🔹 "Data were VERY excellent in terms of efficacy and also in terms of safety" 🔹 "Best-in-Class EASI-75 almost Best-in-Disease type of efficacy" 🔹 "intriguing"  
[X Link](https://x.com/FormalyTwilter/status/2022424256702030042)  2026-02-13T21:34Z [---] followers, [---] engagements


"RT @TakayamaJoe:  214807.2"  
[X Link](https://x.com/FormalyTwilter/status/2023256652204642619)  2026-02-16T04:42Z [---] followers, [---] engagements


"$UTHR UnitedTherapeutics  MiroliverELAP Phase1  $UTHR United Therapeutics Announces Positive Results from Phase [--] Study of miroliverELAP in Patients with Acute Liver Failure https://t.co/b2xFAJ2uJe $UTHR United Therapeutics Announces Positive Results from Phase [--] Study of miroliverELAP in Patients with Acute Liver Failure https://t.co/b2xFAJ2uJe"  
[X Link](https://x.com/FormalyTwilter/status/2016097879367270841)  2026-01-27T10:36Z [---] followers, [--] engagements


"$RHHBY GLP-1/GIP CT-388 Phase2 $LLY $NVO $VKTX $RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://t.co/k6KIIIUF8I $RHHBY Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. $LLY $NVO $VKTX https://t.co/k6KIIIUF8I"  
[X Link](https://x.com/FormalyTwilter/status/2016103232540704849)  2026-01-27T10:57Z [---] followers, [---] engagements


"$ASPI $QLE $SKBL $QLE IPO HALEU ( ) $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand. https://t.co/suZSl9Ok1p $ASPI $QLE $SKBL Graphic we recently put together to help better understand how these companies connect. $QLE will be interesting to see how IPO and HALEU deadlines pan out. TerraPower made it clear $ASPI was the only company who could meet their timeline and demand."  
[X Link](https://x.com/FormalyTwilter/status/2017234686771441905)  2026-01-30T13:53Z [---] followers, [---] engagements


"$GRAL Galleri Multi-Cancer PMA  $GRAL Submits PMA for the Galleri Multi-Cancer Early Detection Test $GRAL Submits PMA for the Galleri Multi-Cancer Early Detection Test"  
[X Link](https://x.com/FormalyTwilter/status/2017245050833691019)  2026-01-30T14:34Z [---] followers, [--] engagements


"$GRAL GRAIL 2026129GalleriPMA [------------] Grok @BioStocks @grok when can we expect news from $GRAL about this @BioStocks @grok when can we expect news from $GRAL about this"  
[X Link](https://x.com/FormalyTwilter/status/2017245763382935699)  2026-01-30T14:37Z [---] followers, [---] engagements


"$GRAL FDA [---] @BioStocks @grok when can we expect news from $GRAL about this @BioStocks @grok when can we expect news from $GRAL about this"  
[X Link](https://x.com/FormalyTwilter/status/2017245845381656671)  2026-01-30T14:37Z [---] followers, [---] engagements


"$IOVA / $IBRX McKesson + 2027Q2 24/25 [--] $IOVA May see rolling catalysts like $IBRX UK Approval Q1 '26 Australia (Prio Rev) Appr Q1 '26 Swiss (Prio Rev) Appr Q1 '26 IOV-END-201 Data Q1 '26 Earnings McKesson ramp-up impact + Canada Cash till Q2 [----] It dawned on me that shitty 24/25 may be a blessing in '26 $IOVA May see rolling catalysts like $IBRX UK Approval Q1 '26 Australia (Prio Rev) Appr Q1 '26 Swiss (Prio Rev) Appr Q1 '26 IOV-END-201 Data Q1 '26 Earnings McKesson ramp-up impact + Canada Cash till Q2 [----] It dawned on me that shitty 24/25 may be a blessing in '26"  
[X Link](https://x.com/FormalyTwilter/status/2017269885257335161)  2026-01-30T16:13Z [---] followers, [---] engagements


"$GUTS Fractyl Health Revita FDA PMA DeNovo [--] FDA [-----] ( ) $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 [----]. $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 2026"  
[X Link](https://x.com/FormalyTwilter/status/2017282219468018096)  2026-01-30T17:02Z [---] followers, [---] engagements


"$GUTS ( ) REMAIN-1 Revita GLP-1  64.5%7.5% [-------] $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 [----]. $GUTS Fractyl Health shares sank to a 52week low as it may shift Revitas FDA path from PMA to De Novo; FDA feedback due Q2 [----]. In REMAIN1 Revita cut postGLP1 weight regain (4.5% vs 7.5% at [--] months) with good safety; 12month data Q3 2026"  
[X Link](https://x.com/FormalyTwilter/status/2017282642958553400)  2026-01-30T17:03Z [---] followers, [---] engagements


"$TERN $TERN M&A 👍 TERN-701 CML $MRK $RVMD It seems that there are some M&A speculations surrounding $TERN. 👍 TERN-701 could be another CML blockbuster. Would not be surprised if $MRK is interested. $RVMD It seems that there are some M&A speculations surrounding $TERN. 👍 TERN-701 could be another CML blockbuster. Would not be surprised if $MRK is interested. $RVMD"  
[X Link](https://x.com/FormalyTwilter/status/2017343414485061984)  2026-01-30T21:05Z [---] followers, [---] engagements


"$RGEN [-------] [----]  $RGEN cash of $18.9B in cash and $1.99B in long-term debt. [----] the year they make bigger deals $RGEN cash of $18.9B in cash and $1.99B in long-term debt. [----] the year they make bigger deals"  
[X Link](https://x.com/FormalyTwilter/status/2017348799061221544)  2026-01-30T21:26Z [---] followers, [--] engagements


"$QURE 🦉 UniQure FDA   FDA STA T TheReadoutLOUD  $QURE 🦉 UniQure to meet with U.S. Food and Drug Administration on Huntingtons gene therapy after the agency changed its view on the trial; patients discussed petitions on STATs The Readout LOUD https://t.co/ZpEfZhS3O0 $QURE 🦉 UniQure to meet with U.S. Food and Drug Administration on Huntingtons gene therapy after the agency changed its view on the trial; patients discussed petitions on STATs The Readout LOUD https://t.co/ZpEfZhS3O0"  
[X Link](https://x.com/FormalyTwilter/status/2017351788299751703)  2026-01-30T21:38Z [---] followers, [---] engagements


"$CAPR FDA HOPE-3 Deramiocel BLA 🧬 DMD  📈 $CAPR just provided a major regulatory update on the Deramiocel BLA following FDA review of HOPE-3 data. 🧬 The market is laser-focused on the DMD approval timeline. Is the path to commercialization fully de-risked or are we facing a "delay-trap" 📈 $CAPR just provided a major regulatory update on the Deramiocel BLA following FDA review of HOPE-3 data. 🧬 The market is laser-focused on the DMD approval timeline. Is the path to commercialization fully de-risked or are we facing a "delay-trap" 📈"  
[X Link](https://x.com/FormalyTwilter/status/2018395444519501836)  2026-02-02T18:45Z [---] followers, [---] engagements


"$TLPH   CRRT [--]   🧵 $TLPH Nafamostat cant compete with heparin because heparin is cheap and established imo. That leaves the other [--] % of CRRT market competing against citrate and no anticoagulation. 🧵 $TLPH Nafamostat cant compete with heparin because heparin is cheap and established imo. That leaves the other [--] % of CRRT market competing against citrate and no anticoagulation. 🧵"  
[X Link](https://x.com/FormalyTwilter/status/2018810845879587301)  2026-02-03T22:16Z [---] followers, [--] engagements


"$TLPH   CRRT  Citrate is expensive complex and is barely used in US. Docs rather not anticoagulate at all and pay for extra CRRT filters that clot more frequently due to no anticoagulation. Citrate is expensive complex and is barely used in US. Docs rather not anticoagulate at all and pay for extra CRRT filters that clot more frequently due to no anticoagulation"  
[X Link](https://x.com/FormalyTwilter/status/2018811252068560944)  2026-02-03T22:18Z [---] followers, [--] engagements


"$TLPH  CRRT ( ) So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500. So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500"  
[X Link](https://x.com/FormalyTwilter/status/2018812103788990503)  2026-02-03T22:21Z [---] followers, [--] engagements


"$TLPH ( )   [---] So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500. So real competition for nafamostat is no anticoagulation. Commercial incentive to anticoagulate is prolonging CRRT filter life. Nafamostat will likely double filter life so hospitals will need half as many filters if they use nafamostat. One filter is $500"  
[X Link](https://x.com/FormalyTwilter/status/2018812367979917616)  2026-02-03T22:22Z [---] followers, [--] engagements


"$TLPH [---]  [---------] ( ) [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life. [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life"  
[X Link](https://x.com/FormalyTwilter/status/2018812810437022064)  2026-02-03T22:24Z [---] followers, [---] engagements


"$TLPH ( ) $TLPH [--] [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life. [--] million filters used in US per year. By using nafamostat vs no anticoagulation hospitals would need 300-400 thousand filters less so $175 million in cost savings per year. So $tlph peak sales estimate $200 mil seems realistic depending on final numbers of filter life"  
[X Link](https://x.com/FormalyTwilter/status/2018813070861378035)  2026-02-03T22:25Z [---] followers, [---] engagements


"@cluelessbio $TLPH"  
[X Link](https://x.com/FormalyTwilter/status/2018813913933172774)  2026-02-03T22:28Z [---] followers, [--] engagements


"$TLPH $CRMD [--] $TLPH $CRMD    ( ) https://x.com/BussinBiotech/status/1899912549551783956 Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full https://x.com/BussinBiotech/status/1899912549551783956 Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year."  
[X Link](https://x.com/FormalyTwilter/status/2018819793026265306)  2026-02-03T22:52Z [---] followers, [---] engagements


"$TLPH $CRMD [----] $CRMD $TLPH [----] Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full Back in March I highlighted the connection between $TLPH and $CRMD well before the private placements and strategic investments were announced publicly later in the year. https://t.co/KGp8z7HhgZ I fully expect my thesis to continue to play out culminating in a full"  
[X Link](https://x.com/FormalyTwilter/status/2018820072077471919)  2026-02-03T22:53Z [---] followers, [---] engagements


"$NUVB 1/1/25 $NUVB 2025/Q4 $NUVB Sagard Ibtrozi 5.5% [--] [-----]  $NUVB share price since 1/1/25. Does NUVB's "fall" since releasing Q425 sales appear to be turning Sagard invested $150MM to purchase a 5.5% Ibtrozi royalty (roughly a $2.7B valuation.as a royalty). This is not investment advice. $XBI $IBB $NBI https://t.co/MeEiKosB1Y $NUVB share price since 1/1/25. Does NUVB's "fall" since releasing Q425 sales appear to be turning Sagard invested $150MM to purchase a 5.5% Ibtrozi royalty (roughly a $2.7B valuation.as a royalty). This is not investment advice. $XBI $IBB $NBI https://t.co/MeEiKosB1Y"  
[X Link](https://x.com/FormalyTwilter/status/2019084973219733525)  2026-02-04T16:25Z [---] followers, [---] engagements


"$RLAY   CDK4/6 PIK3CAHR+/HER2- * FDA  BTD * ( ) #PDUFA #FDA # # #  $RLAYCDK4/6PIK3CAHR+/HER2-**FDABTD** $RLAYCDK4/6PIK3CAHR+/HER2-**FDABTD**"  
[X Link](https://x.com/FormalyTwilter/status/2019791150513521112)  2026-02-06T15:11Z [---] followers, [---] engagements


"RT @DeNebulord: $aspi could it get to $4 It's possible based on HTF support. But cash per share $2 so seems hard to believe https://t.co"  
[X Link](https://x.com/FormalyTwilter/status/2019884334543696173)  2026-02-06T21:22Z [---] followers, [--] engagements


"$XFOR $XFOR $4.23$4.50 $5 $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips. $XFOR: XFOR defended $4.23; reclaim $4.50 and youre back in trend-rebuild mode. Options lens: $5 is the key strike to watch if momentum flips"  
[X Link](https://x.com/FormalyTwilter/status/2009001309928861989)  2026-01-07T20:36Z [---] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing